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Reproducibility and transparency in scientiﬁc reporting is paramount to advancing science and providing
the foundation required for sound regulation. Recent examples demonstrate that pivotal scientiﬁc
ﬁndings cannot be replicated, due to poor documentation or methodological bias, sparking debate across
scientiﬁc and regulatory communities. However, there is general agreement that improvements in
communicating and documenting research and risk assessment methods are needed. In the case of
formaldehyde, the peer-review conducted by a National Academy of Sciences (NAS) Committee ques-
tioned the approaches used by the Integrated Risk Information System (IRIS) in developing draft unit risk
values. Using the original data from the key study (Beane Freeman et al., 2009) and documentation
provided in the draft IRIS proﬁle, we attempted to duplicate the reported inhalation unit risk values and
address the NAS Committee's questions regarding application of the appropriate dose-response model.
Overall, documentation of the methods lacked sufﬁcient detail to allow for replication of the unit risk
estimates, speciﬁcally for Hodgkin lymphoma and leukemias, the key systemic endpoints selected by
IRIS. The lack of apparent exposure-response relationships for selected endpoints raises the question
whether quantitative analyses are appropriate for these endpoints, and if so, how results are to be
interpreted.
© 2016 Published by Elsevier Inc.1. Introduction
Reproducibility and transparency in scientiﬁc research and
reporting, both in the published literature and in documentation of
decisions related to public health reached by authoritative bodies,
have received signiﬁcant discussion and debate (Bustin and Nolan,
2015; Campbell, 2014; Igbal et al., 2016; Jilka, 2016). The National
Institutes of Health (NIH) are exploring ways to provide greater
transparency of the data that are the basis for published manu-
scripts (Collins and Tabak, 2014) and have noted that the greater
scientiﬁc community must take steps to correct this issue. In
addition, recent commentaries and surveys highlight the growing
lack of reproducibility in scientiﬁc research (Anonymous, 2016).
One of the most immediate and impactful consequences for a lack).of transparency or reproducibility is in the direct reliance on pub-
lished but un-replicated scientiﬁc ﬁndings for human health risk
assessment, including the derivation of cancer unit risk estimates.
In 2011, the National Research Council (NRC) of the National
Academy of Sciences (NAS) convened a Committee to Review
USEPA's Draft of the Toxicological Review of Formaldehyde e Inha-
lation Assessment in support of the Integrated Risk Information
System (IRIS) (NRC, 2011). The Committee noted:
“Problems with clarity and transparency of the methods appear to
be a repeating theme over the years, even though the documents
appear to have grown considerably in length”
A further review of the IRIS process in 2014 (NRC, 2014) noted
progress in meeting the NRC (2011) recommendations, but further
noted:
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some of the more complex and challenging IRIS assessments in the
last decade and have identiﬁed methodologic problems and
pointed out deﬁciencies in EPA's approaches.”
Formaldehyde provides one such complex database that in-
troduces signiﬁcant challenges for consideration in a standard IRIS
assessment. It is an endogenously generated compound and, for
selected endpoints, multiple studies provide inconsistent results, a
few of which have suggested associations with formaldehyde
exposure. Some have interpreted these ﬁndings (generally at face
value and apart from the larger body of results) as reﬂecting causal
associations. As an example, there has been much scientiﬁc debate
regarding whether there is a causal association between formal-
dehyde exposure and selected lymphohematopoietic (LHP) end-
points, especially acute myeloid leukemia. Multiple authoritative
bodies (IARC, 2012; NTP, 2014) have made hazard classiﬁcation
decisions (sufﬁcient evidence in humans, known to be a human
carcinogen) based on conclusions that the available evidence is
sufﬁcient to conclude that there is a causal association. For the LHP
cancers, these conclusions have been based on the grouping of
different types of cancers from a limited number of epidemiological
studies (Zhang et al., 2009; Beane Freeman et al., 2009), with little
or no consideration of ﬁndings reported in many other studies or
the animal or mechanistic information, much of which lends no
support for or even contradicts these conclusions. It is important to
note that in reviewing the same critical studies for formaldehyde as
IARC (2012) and NTP (2014), the European Chemicals Agency
(ECHA, 2011) concluded that
“Altogether, in absence of convincing evidence for a biologically
plausible mechanism and considering the discrepancy of results in
epidemiological studies, a causal relationship between formalde-
hyde exposure and induction of myeloid leukaemia cannot be
concluded.”
The 2010 draft IRIS Toxicological Review of Formaldehyde e
Inhalation Assessment provided the ﬁrst quantitative estimates of a
dose-response relationship between two lymphohematopoietic
endpoints, Hodgkin lymphoma (HL) and all leukemias (combined
category), and exposure to formaldehyde based on the results from
a single epidemiological study (Beane Freeman et al., 2009). The
use of these two endpoints by USEPA (2010) for the estimation of
unit risk factors was based on the conclusion that the weight of the
epidemiologic evidence supported a link between formaldehyde
exposure and LHP cancers, particularly myeloid leukemias. In
addition to HL largely being considered unrelated to environmental
exposures, no other key epidemiological study demonstrates such
an association, raising questions as to the validity of the ﬁnding in
Beane Freeman et al. (2009). As for the combination of all leuke-
mias, little scientiﬁc basis is provided for aggregating what
increasingly are understood to be diverse diseases with different
etiologies, prognoses and treatments.
In 2011, the NRC Committee review noted many uncertainties in
the approach used by USEPA (2010) to estimate risk values. The
Committee recognized that USEPA (2010) had relied upon selected
associations reported between formaldehyde and various LHP
cancers from a single study (Beane Freeman et al., 2009). The NRC
(2011) Committee further recommended that USEPA conduct an
independent analysis of the dose-response models to conﬁrm the
degree to which the models ﬁt the data appropriately, as well as
consider the use of alternative extrapolationmodels for the analysis
of the cancer data. The NRC (2011) Committee concluded that this is
especially important, given the use of a single study, theinconsistencies in the exposure measures, and the uncertainties
associated with the selected cancers. In addition to the impact of
these assumptions, the NRC (2011) Committee noted that while the
National Cancer Institute (NCI) cohort studies, including Beane
Freeman et al. (2009), may be the only studies with sufﬁcient
exposure and dose-response data needed for risk estimation, they
are not without weaknesses and these need to be considered. This
recommendation from the NRC (2011) Committee raised several
challenges. While there is some guidance provided for the use of
animal data for dose-response modelling (USEPA, 2012), the use of
epidemiological data in the estimation of inhalation unit risk (IUR)
estimates does not have guidance that provides a “road map” for
conducting these types of assessments. When using epidemiolog-
ical data for the estimation of unit risk values, more extensive
documentation in the IRIS proﬁle is needed to be able to clearly
understand the data relied upon and the methods applied.
In a separate study (Checkoway et al., 2015), the raw data from
the NCI cohort study (Beane Freeman et al., 2009) were obtained
through a Technology Transfer Agreement (TTA) with the objective
of replicating the ﬁndings reported by Beane Freeman et al. (2009),
as well as conducting additional analyses not reported by Beane
Freeman, speciﬁcally, acute myeloid leukemia (AML). The avail-
ability of these data provided an opportunity to attempt to replicate
the unit risk estimates derived by USEPA (2010), as well as address
some of the questions raised by NRC (2011). In addition, it offered
the opportunity to conduct alternate independent analyses to
evaluate speciﬁc leukemias, rather than all leukemias combined,
and the impact of alternate dose-response models on the estimates
of inhalation unit risk. The methods and results of the attempt to
duplicate the USEPA (2010) unit risk values, as well as conduct
alternate and independent analyses to address the questions raised
by NRC (2011) are reported here.
2. Methods
2.1. Duplication of USEPA (2010) reported unit risks
Our goal was to follow the same process and methods used by
USEPA (2010) in the estimation of unit risk factors for the two LHP
cancers (Hodgkin Lymphoma and all leukemias (combined cate-
gory)). However, as noted by NRC (2011), the documentation pro-
vided in USEPA (2010) related to the assumptions and processes
used in the estimation of the unit risk values was limited. NRC
(2011) has outlined ﬁve steps that it appears USEPA (2010) used
in the estimation of formaldehyde unit risks:
1. Evaluate the association between formaldehyde exposure and
LHP endpoints;
2. Convert the relative risk estimates into lifetime risk for the
exposed population;
3. Compute lifetime risks for Hodgkin Lymphoma and/or all leu-
kemia for the unexposed population;
4. Determine the maximum likelihood and lower bound estimates
of the point of departure; and
5. Estimate inhalation unit risks.
Using these ﬁve steps, we attempted to duplicate the USEPA
(2010) reported unit risks for Hodgkin lymphoma and “all leuke-
mias” using the raw data from the Beane Freeman et al. (2009)
study. In order to conduct this estimate, the followingwere needed:
▪ An estimate of cumulative dose for each individual in the cohort.
This information was not provided in either USEPA (2010) or
Beane Freeman et al. (2009) and must be determined from the
raw data.
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(2010) or Beane Freeman et al. (2009) and must be determined
from the raw data.
Absent this necessary information and with no data available to
conﬁrm how it was used in estimating risk, assumptions were
necessary that impact the estimation of parameters characterizing
the relationship between dose and response.
NRC (2011) also recommended that the evaluation of the
epidemiological data focus on themost speciﬁc diagnoses available.
Based on this recommendation, analyses were conducted to
include the consideration of individual LHPs rather than combi-
nation of endpoints (e.g. all leukemias) and evaluation of alternate
dose-response models for these individual endpoints. While the
impact of dose metric selection (e.g., ‘peak’1 versus cumulative) has
been a point of discussion in interpretation of the NCI cohort
(Checkoway et al., 2015), speciﬁcally the lack of actual peak mea-
sures or estimates, the USEPA (2010) has noted that cumulative
exposure is generally the preferred metric for quantitative risk
assessment and was relied upon for the estimation of unit risk
values. Therefore, the analyses reported below focused on cumu-
lative exposure estimates based on the data obtained through the
TTA and reported in Beane Freeman et al. (2009) and Checkoway
et al. (2015).
2.2. Evaluation of model selection
NRC (2011) noted that informationwas needed on the degree to
which the model used (i.e., Poisson regression model) ﬁts the data,
especially for dose-response analysis. NRC (2011) further noted that
this type of analysis is essential because dose-response models for
risk estimation must ﬁt the data well in the low-dose range and
alternative extrapolation models, including Cox regression models
and nonlinear model forms, should be considered in order to
identify the best-ﬁtting model. We conducted additional analyses
to evaluate the potential impact of NRC (2011) comments on both
the methods and the data relied upon for unit risk estimation, as
well as consideration of multiple models. In addition to a Poisson
regression model, the logistic regression model was considered, as
well as a Cox regression model that was applied to the data from
Beane Freeman et al. (2009) by Checkoway et al. (2015). All models
used a 2-year lag for exposure, which is consistent with a lag
considered by both Beane Freeman et al. (2009) and Checkoway
et al. (2015).
A log-linear Poisson model, which is the model reported by
Beane Freeman et al. (2009) to estimate the exposure-response
relationship (b values), was used to compare the results in this
analysis to the results published in Beane Freeman et al. (2009) in
which the cumulative 2-year lag exposure variable was categorized
into discrete exposure variables using the 4 categories reported
(0 ppm-years, >0 and < 1.5 ppm-years, 1.5 and < 5.5 ppm-years,
and 5.5 ppm-years). A log-linear Poisson model was also ﬁt using
the discrete dose categories reported by Checkoway et al. (2015)
(<0.5 ppm-years, 0.5 and < 2.5 ppm-years, and 2.5 ppm-
years). In addition, both a log-linear Poisson model and a logistic
regressionmodel were ﬁt to the data using a categorization scheme
for the 2-year lag cumulative dose that split the data into quartiles
so that an approximately equal number of subjects were in each
group (<0.05 ppm-years,  0.05 and < 0.4 ppm-years, 0.4
and < 2.4 ppm-years, and 2.4 ppm-years). All models were run
considering person-time at risk, sex and race and adjusted for pay1 The ‘peak’ exposure metric used in Beane Freeman et al. (2009) is a relative
peak estimator described in Stewart et al., 1986.type (i.e., hourly vs. salary). For the logistic and Poisson models,
quadratic terms for exposure were also considered. For evaluation
of potential model ﬁt to the data in the low concentration region, a
visual examination of the Poisson and log-logistic model estimates
were compared to the case status at the end of follow-up for each
individual, again considering person-time at risk, sex, race and pay
type.
3. Results
3.1. Duplication of USEPA (2010) reported unit risks
3.1.1. Step 1 e evaluate the association between formaldehyde
exposure and LHP endpoints
The attempt to estimate the unit risks reported in USEPA (2010)
was initiated using the model parameters (b parameters from the
log-linear Poisson regression model) provided to USEPA via per-
sonal communication by Dr. Laura Beane Freeman. The b parame-
ters describe the relationship between exposure and response.
Prior to estimating the unit risk, using the raw data, we attempted
to replicate the model parameter estimates provided to the USEPA
(2010) by Dr. Beane Freeman using log-linear Poisson regression,
which is the same modelling approach reported to have been used
to develop these estimates in both the Beane Freeman et al. (2009)
publication and in the draft IRIS evaluation (USEPA, 2010) (Table 1).
In addition, Cox and logistic regression models were considered.
Since cumulative exposure was the focus of the USEPA (2010)
unit risk estimates, an initial analysis to evaluate the association
between this exposure metric and the two endpoints relied upon
for unit risk estimates (i.e., Hodgkin lymphoma and all leukemias
combined) was conducted. Several variables were needed from the
raw data, including the estimate of cumulative exposure (ppm) for
each individual and person time at risk for each individual, neither
of which are provided in USEPA (2010) or Beane Freeman et al.
(2009) and had to be estimated from the raw data. In addition, in
order to estimate the b parameters, the raw data regarding the
number of deaths from a speciﬁc cancer and corresponding expo-
sure metric must be divided into the same exposure quartiles as
those reported by Beane Freeman et al. (2009) to evaluate the
exposure-response relationship.
For the current analyses, the following steps were conducted to
identify the data needed for analysis.
1. Using the work history data and date of birth, the data records
were combined and organized to result in one or more record
for each job so that no record spanned a calendar year or a
change in age. Calculation of the duration of each work record
was performed in this step with consideration of leap years.
Since only start and stop months of work were provided in the
raw data from Beane Freeman et al. (2009), the initial start and
ﬁnal stop day for a jobwere assumed to be the 15th of themonth
unless the start and stop months were the same month in the
same year. In this case, the stop day was assumed to be the
appropriate value for the end of the month (28, 29, 30 or 31).
The gender, race, salary code and status of each individual (alive
or dead) and cause of death ICD code were also attached to the
individual's record.
2. The exposure and duration of exposure were summed over the
months in a year when the individual was a speciﬁc age. During
this step, the peak exposure category for each work record was
determined.
3. The cumulative and lagged cumulative exposure and person-
years of exposure were calculated.
4. The records were categorized into the strata of ranges of years
(groups covering a 5 year period starting with 1960 and ending
Table 1
Comparison of modelling statistics from the current analysis to statistics reported in USEPA (2010).
Current analysis USEPA (2010)
Cox regression Logistic regression Poisson regression
p-
value
a
b (per
ppm x
year)
Standard
error (per
ppm x year)
R2 LR p-
valueb
p-
value
a
b (per
ppm  year)
Standard
error (per
ppm  year)
LR p-
valueb
p-
value a
b (per
ppm  year)
Standard
error (per
ppm  year)
p-
value
b (per
ppm  year)
Standard
error (per
ppm  year)
Hodgkin
lymphoma
(201)
0.013 0.0294 0.0119 0.0133 0.098 0.019 0.0288 0.0123 0.09 0.037 0.0243 0.0117 0.02959 0.01307
Leukemia
(204e207)
0.058 0.0117 0.0062 0.0017 0.35 0.055 0.0121 0.00628 0.003 <0.001 0.0206 0.0057 0.08 0.01246 0.000642
Leukemia
(204e207,
excluding
204.1)
0.239 0.0092 0.0079 0.0011 0.64 0.206 0.01 0.00791 0.034 0.013 0.018 0.0073 e e e
Acute
myeloid
leukemia
(205.0)
0.844 0.004 0.0201 0.0016 0.82 0.869 0.0032 0.0196 0.81 0.80 0.0045 0.0179 e e e
Cox regression model h(t,x) ¼ h0(t) exp(bx þ gz).
Logistic regression model Y ¼ 1/[1 þ exp(a þ bx þ gz)].
Poisson regression model Ln(Y/t) ¼ a þ bx þ gz OR Y ¼ t exp(a)  exp(bx))  exp(gz).
Where Y is the expected number of events, a is the intercept, b is the slope term, x is the exposure, z is a covariate and t is the duration of exposure. In the Cox model h is the
hazard rate.
a These p-values reﬂect the precision of any association between exposure and response, and show the probability that the beta value is not signiﬁcantly different from zero.
P-values < 0.5 indicate that the beta parameter is signiﬁcantly different from zero.
b The likelihood ratio p-values of difference between a null and dose-dependent model (e.g. test of b ¼ 0) where small p-values reject the hypothesis that b ¼ 0.
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starting with the age of 15 and ending with 85), where the
lowest year group included all records prior to 1965, and the
1965 group included years 1965 through 1969, with all job re-
cords occurring in 2010 and after included in the 2010 category.
For ages, all ages less than 20 were included with the 15 year old
age group, and the second group labelled 20 included all ages
from 20 through 29.
5. The ﬁnal record for each individual included an indication of
dead or alive. For those individuals who had died, the ICD codes
were used to set up yes/no ﬂags indicating whether Hodgkin
lymphoma, leukemia or acute mylogenous leukemiawere found
in that individual.
This process resulted in 1,047,291 work records that were then
used in the analyses. All analyses used stratiﬁcation for age group,
year group, gender and race, with all the models adjusted for salary
type treated as a classiﬁcation variable. The Poisson analysis (SAS
Proc Genmod) used a Poisson distribution, a log link and an offset of
the natural log of the cumulative person-years of exposure. SAS
Proc Logistic was used to perform the logistic regression and Cox
proportions hazards models were performed using STATA
(Checkoway et al., 2015).
Beane Freeman et al. (2009) reported that the cut points for the
exposure groups were based on the approximate 60th and 80th
percentiles from the cumulative exposures for those subjects with
cancer. In attempting to duplicate the number of cancers within
each exposure group, the cut points of 1.5 and 5.5 ppm-years (cu-
mulative exposure groups deﬁned by Beane Freeman et al. (2009)
as 0 to 1.5, 1.5 to <5.5, 5.5 ppm-years) could not be duplicated
based on the estimated 60th and 80th percentiles using the raw
data. The calculations for the current assessment resulted in the
determination of 1.2 and 4.2 ppm-years as the 60th and 80th per-
centiles for the cumulative exposure of the subjects with cancer. In
addition, the number of unexposed workers (4359) reported by
Beane Freeman et al. (2009) could not be replicated. Using the raw
data, only 2676 unexposed workers could be identiﬁed.3
Regardless of the lack of ability to duplicate this determinationof exposure, an evaluation of the exposure-response relationship
was conducted. For the “all leukemia” category, exposure-response
was evaluated including and excluding chronic lymphocytic leu-
kemia (CLL), because, as noted by Checkoway et al. (2015), CLL has
been classiﬁed as a non-Hodgkin lymphoma (NHL) since 2001
(Muller-Hermelink et al., 2001; Campo et al., 2011).
Other models were attempted in this process. Using quadratic
terms for exposure failed to provide any better ﬁt of the models to
the data. In addition, the effect of exposure to other substances
were explored but these did not improve the model ﬁts substan-
tially, either.
As noted in Table 1, in attempting to duplicate the b parameter
and standard error for each cancer type, similar values could be
estimated, but the estimates reported in USEPA (2010) could not be
duplicated, which can impact attempting to duplicate unit risk
estimates. In addition, it is important to note that no signiﬁcant
association between leukemia as a class of diseases
(p-values > 0.05; Table 1) or speciﬁcally for acute myeloid leukemia
(p  0.8) with cumulative exposure to formaldehyde was found
(using the typical 0.05 as the determinant of “signiﬁcant”) for either
the Cox regression or the logistic regression. In addition, the esti-
mated b parameter for acute myeloid leukemia (~-0.004 from the
Cox regression and the logistic regression) indicates that the slope
is in the negative direction (decreasing incidence with increasing
exposure). These results for AML suggest that it would not be
appropriate to rely upon these negative data independently in the
dose-response modelling for the estimation of a unit “protection”
estimate. As imprecise positive estimates of a b parameter should
not be interpreted as evidence of risk, imprecise negative b pa-
rameters should not be interpreted as beneﬁcial or protective. For
all the logistic models, the likelihood ratio test indicates that the b
parameter is not statistically different from zero. Similarly the
likelihood ratio test of the Poisson models for Hodgkin lymphoma
and the acute myeloid leukemia also indicate that the b parameter
is not statistically different from zero. Only for the Poisson models
of combined leukemias are the b values considered to be statisti-
cally signiﬁcantly different from zero. However, as these are
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NRC (2011) and there is almost a factor of 2 difference between the
b estimates between the different models in the current analysis
and the USEPA (2010) b estimate, there is still large uncertainty in
the results.
The estimated b parameter for Hodgkin lymphoma was com-
parable to that reported in USEPA (2010); however, there was a
difference in the standard error and a larger difference in the p-
values. USEPA (2010) reported a non-signiﬁcant trend between
cumulative formaldehyde exposure and Hodgkin lymphoma based
on information reported in Beane Freeman et al. (2009), while the
current analysis suggested a signiﬁcant trend (p-value ¼ 0.013).
These results are consistent with those reported by Checkoway
et al. (2015). However, Checkoway et al. (2015) notes that the
increased risk of HL has not been observed in other occupational
studies of formaldehyde-exposed cohorts, and is not regarded as
plausibly related to environmental chemical exposures.
Because the b parameters could not be duplicated, it was
concluded that while additional steps could be conducted to eval-
uate the transparency of the process, the lack of ability to duplicate
this ﬁrst step would result in a lack of ability to duplicate the re-
ported unit risks. Even having access to the raw data from the
Beane Freeman et al. (2009) study, there were not enough details
regarding themethods used to evaluate the data provided in USEPA
(2010) to duplicate the initial b parameters necessary to initiate the
unit risk estimate process.3.1.2. Step 2 e convert the relative risk estimates into lifetime risk
for the exposed population
Relying strictly on the b parameters reported in USEPA (2010),
even though they could not be duplicated, an attempt was made to
conduct the remaining steps of the estimation of unit risk as out-
lined by NRC (2011). USEPA (2010) noted that the b parameters
were used in a life table analysis to calculate lifetime extra cancer
risks from formaldehyde exposure. This step, as well as step 3, re-
quires the use of a life-table method in conjunction with (a) the
Poisson model mortality risk, (b) age-speciﬁc all-cause mortality
rate in the United States population, and (c) Hodgkin lymphoma
and all leukemia mortality rates, all of which can be derived from
the NCI's Surveillance, Epidemiology and End Results (SEER) data-
base. SEER collects cancer incidence data from multiple
geographical areas in the United States. This step also requires es-
timates of the effective concentration (EC) for occupational expo-
sure adjusted to continuous ambient exposure (the standard
exposure metric relied upon by USEPA in the estimation of a unit
risk) by multiplying by the ratio of days in a year to work days (240,
50 weeks of 5 dayworkweeks) and the ratio of daily inhalation rate
(20 m3) to work day inhalation rate (10 m3) (USEPA, 2010).
EC ¼ exposure ðppmÞ  365
240
 20
10
USEPA (2010) provided a spreadsheet (Appendix C of USEPA,
2010; Supplemental Tables S1 and S2) illustrating the life table
used for the extra risk calculation for the derivation of the LEC0005
(95% lower conﬁdence limit on the effective concentration corre-
sponding to an extra risk of 0.05%) relied upon for estimating the
IUR based on nasopharyngeal (NPC) mortality reported by
Hauptmann et al. (2004). USEPA (2010) noted that the same general
methodology described for NPC mortality estimates was used for
Hodgkin lymphoma and leukemias, with the following exceptions:
 U.S. age-speciﬁc 2006 all-cause mortality rates (NCHS, 2009); NCHS age-speciﬁc 2002e2006 background mortality rates for
Hodgkin lymphoma and leukemia (http://seer.cancer.gov/csr/
1975-2006/) for all race and gender groups; and
 A 2-year lag period instead of a 15-year lag period.
It is important to note that USEPA (2010) provided no citation
for the NCHS (2009) all-cause mortality rates, so it was assumed
this was obtained from the NCHS website (http://www.cdc.gov/
nchs/data/nvsr/nvsr57/nvsr57_14.pdf) as the background mortal-
ity rates for speciﬁc cancers (Heron et al., 2006). While this does
provide data needed to allow the assessor to attempt to duplicate
this procedure, there is no comparable life-table for Hodgkin
lymphoma or all leukemias to ensure that comparable results are
achieved. Relying upon these sources and following these ap-
proaches, the IURs provided in USEPA (2010) could not be dupli-
cated using the reported sources and methodology. This was also
true for NPC for which the life table was provided (Appendix C;
USEPA (2010)). In attempting to duplicate the IURs reported for
NPC, it was determined that the values reported from the use of the
life table instructions provided could not produce the reported IURs
for NPC (see supplemental Table S1 for the re-creation of the cal-
culations that would correspond to the unit risks reported in USEPA
(2010) when using the instructions provided by USEPA (2010) for
Table C-1. The difﬁculty in duplicating the life table reported was
related to the function reported for estimating the NPC incidence
hazard rate (Column L in Supplemental Table 2). Using the USEPA
(2010) b of 0.0518 (SE 0.01915) and the calculations as speciﬁed
in Table C-1 of USEPA (2010), the estimated EC0005 and LEC0005
would be 0.103 and 0.0623 ppm, respectively, with a unit risk of
8  103. However, the calculations speciﬁed in Appendix C of
USEPA (2010) indicated a function for the hazard incidence rate of
hxi ¼ hi  (1 þ b  xdose) which is inconsistent with the model of
risk that was used to determine the b value (RR ¼ ebX , where b
represents the regression coefﬁcient for exposure and X is exposure
as a continuous variable) (USEPA, 2010). When the hazard rate
function is changed to hxi ¼ hi  (eb  xdose) to properly reﬂect the
underlying risk function, the values estimated by the revised life
table were the same as those reported by the USEPA in Tables 5e11
for EC0005 and LEC0005 based on NPC incidence for formaldehyde
exposure (0.074 and 0.046 ppm, respectively, see supplemental
Table S3 for the adjusted life-table calculation). However, it is
important to note that these estimates rely upon the b parameters
reported in USEPA (2010), which cannot be duplicated.
3.1.3. Step 3 e compute lifetime risks for Hodgkin Lymphoma and/
or all leukemia for the unexposed population
As noted in USEPA (2010), USEPA cancer risk estimates are
typically derived to represent a plausible upper bound on increased
risk of cancer incidence, typically based on experimental animal
incidence data. However, epidemiological studies more often pre-
sent results based on mortality data, which is true for the Beane
Freeman et al. (2009) study. For cancers with low survival rates,
mortality-based estimates are a reasonable approximation of can-
cer incidence risk. However, USEPA (2010) largely documents its
approach to the evaluation of nasopharyngeal cancers and noted
the need to estimate incidence-based risks. Estimation of the
incidence of a particular cancer type using mortality data can be
conducted by acquiring the age-speciﬁc incidence rates for a spe-
ciﬁc cancer from the SEER program. In order to estimate the po-
tential risk of incidence of a cancer type, the data from the SEER
database are used to adjust the mortality data assuming that the
exposure-response relationship for incidence and mortality of a
cancer type are the same. An examination of the assumptions and
adjustments made to the Beane Freeman et al. (2009) data for
lymphohematopoietic cancers follows.
Table 2
Extra risk estimates for Hodgkin lymphoma mortality from various levels of continuous exposure to formaldehyde (reproduced from Tables 5e14 in USEPA (2010)).
Exposure concentration (ppm) As reported by USEPA (2010) Estimated using the life table provided in USEPA
(2010) a with adjustments to the hazard function
Extra risk 95% UCL on extra risk Extra risk 95% UCL on extra risk
0.0001 2.04  107 3.53  107 2.52  107 4.36  107
0.001 2.05  106 3.55  106 2.53  106 4.38  106
0.01 2.10  105 3.71  105 2.59  105 4.59  105
0.1 2.79  104 6.17  104 3.44  104 7.63  104
1 1.63  101 8.36  101 1.90  101 8.53  101
10 9.89  101 9.90  101 9.89  101 9.90  101
a Using the supplied information in the life table provided in USEPA (2010) with an adjustment in column L for the incidence hazard rate in interval I (hxi ¼ hi  e(b  xdose))
for the estimates of b ¼ 0.02959, SE ¼ 0.01307.
Table 3
Extra risk estimates for leukemia mortality from various levels of continuous exposure to formaldehyde (reproduced from Tables 5e15 in USEPA (2010)).
Exposure concentration (ppm) Calculated by USEPA (2010) Estimated using the life table provided in USEPA
(2010) a with adjustments to the hazard function
Extra risk 95% UCL on extra risk Extra risk 95% UCL on extra risk
0.0001 1.64  106 3.02  106 1.65  106 3.06  106
0.001 1.64  105 3.03  105 1.65  105 3.07  105
0.01 1.66  104 3.10  104 1.67  104 3.13  104
0.1 1.87  103 3.90  103 1.89  103 3.95  103
1 8.07  102 5.19  101 8.16  102 5.28  101
10 9.80  101 9.89  101 9.80  101 9.89  101
a Using US 2006 mortality rates, the adjusted life table structure and potency estimates (b ¼ 0.01246, SE ¼ 0.006421) from USEPA (2010).
Table 4
Relative risk based on peak exposure from Poisson model stratiﬁed by calendar year, age, sex and race and adjusted for pay category.
0 ppm >0 to <2.0 ppm > ¼ 2.0 to <4.0 ppm > ¼ 4.0 ppm
Log likelihood p-value
Total in group 3139 10,302 6010 6168
Person-years 104,386 415,987 254,723 256,618
Cases RR (95% CI) Cases RR (referent) Cases RR (95% CI) Cases RR (95% CI)
Hodgkin lymphoma (201) 2 3.32 (0.60e18.26) 6 1.0 8 0.76 (0.30e1.89) 11 2.96 (0.94e9.27) 309.87 0.04
Leukemia (204e207) 7 1.83 (0.76e4.40) 41 1.0 27 0.58 (0.36e0.93) 48 0.58 (0.36e0.93) 1177.94 0.004
Leukemia (204e207, excluding 204.1) 6 1.61 (0.61e4.24) 28 1.0 20 0.56 (0.32e0.96) 37 1.17 (0.65e2.09) 901.65 0.009
Acute myeloid leukemia (205.0) 4 1.21 (0.33e4.43) 9 1.0 9 0.77 (0.32e1.84) 12 1.72 (0.67e4.43) 374.47 0.34
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tality rates to determine the extra risk from the incidence of the
endpoint of interest, the effect of using background incidence dataFig. 1. Comparison of estimated cases from the Poisson regression model to number of cases
study. Observed and predicted results over full observed exposure range.for Hodgkin lymphoma and all leukemia was explored. The back-
ground mortality rates were adjusted to reﬂect the background
incidence of the endpoint by replacing the mortality rate attributedof leukemia observed at the end of follow-up period in the Beane Freeman et al. (2009)
2 The graphs were constructed using the 5% percentiles (e.g. 5%, 10%, 15%, etc.) of
the cumulative exposure, and sums of the person-years, number of individuals and
number of observed and predicted leukemias per percentile to determine the rates.
The conﬁdence limits for the logistic graph were calculated using binomial conﬁ-
dence limits on the observed rates of leukemia per percentile group of exposure,
and the Poisson conﬁdence limits are exact conﬁdence limits based on the Poisson
distribution.
3 This number of unexposed workers identiﬁed in the current analysis (2676) is
consistent with the number determined by Checkoway et al. (2015) in a separate
reanalysis of the raw data from Beane Freeman et al. (2009) study. When this
difference was discovered by Checkoway et al. (2015), communications with Dr.
Beane Freeman indicated that the number of unexposed workers reported was a
mistake and should have been 3,108. However, Checkoway et al. (2015) could not
duplicate this number of unexposed workers either using the raw data.
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this correction resulted in a difference of between 10 and 21% in the
estimated risks for the current analysis.
3.1.4. Step 4 e determine maximum likelihood and lower bound
estimates of point of departure
USEPA's carcinogenicity risk-assessment guidelines (USEPA,
2005) recommend the use of an extra risk of 1e10% for deriving
effective concentration at the Point of Departure (POD), or for the
USEPA (2010) IRIS assessment. NRC (2011) noted that in USEPA
(2010) there was an unusual choice of a 0.05% extra risk for
Hodgkin lymphoma and 0.5% extra risk for all leukemias. USEPA
(2010) noted the issues with using standard extra risk levels (e.g.,
10%) in that the risks using these standard extra risk assumptions
resulted in relative risk estimates that were substantially higher
than those observed in the epidemiology study. Therefore, the
choice of the extra risk value to use was based on the background
mortality rate for each individual cancer type compared to the
relative risk estimates observed in the Beane Freeman et al. (2009)
study. Relative risk estimates were determined starting at the 10%
extra risk level, decreasing the extra risk level until the relative risk
estimates were within the observable range of the epidemiology
study. For example, if the 1% level of risk associated with the
relative risk estimates for NPC were higher than those observed in
the Beane Freeman et al. (2009) study, the extra risk level of
concern was lowered until the relative risk estimates were below
the relative risk estimates from the Beane Freeman et al. (2009), so
an upward extrapolation could be conducted. This approach
effectively assumes that nothing observed in the Beane Freeman
et al. (2009) could be attributable to background incidence of
these cancer types.
Using the hazard rate function as instructed in the life table
example (Footnote for Column L, Table C-1 of USEPA (2010)), the
extra risk and 95% upper conﬁdence limits on extra risk provided in
USEPA (2010) cannot be reproduced (Tables 2 and 3). However,
using a life table that had a hazard rate function consistent with the
underlying risk function produced results that were similar to those
reported by the USEPA (2010). Supplemental Tables S2 and S4 show
the differences in the risk values calculated at an exposure of 1 ppm
using the USEPA (2010) instructions (Table S2) versus the revised
life table (Table S4) with the modiﬁed hazard function that was
necessary to duplicate the EC, LEC and unit risk values reported in
USEPA (2010). While there was some correspondence, there were
still some differences in the values that were calculated for the
extra risk (Tables 2 and 3) and there is some concern about the
appropriateness of the risk estimates, especially large estimates of
risk for values above 0.1 ppm. An exposure of 0.1 ppm is within the
range of exposures (0.01e4.3 ppm e TWA) reported by Beane
Freeman et al. (2009). The relative risk values estimated for these
exposures approach 100% and are inconsistent with the observed
incidences of cancers in the Beane Freeman et al. (2009) study.
3.1.5. Step 5 e convert the relative risk estimates into lifetime risk
for the exposed population
With the results from step 4, the lower bounds on exposure
(LECx) and the extra risk level should then be used to determine the
unit risks. However, because the model parameters from step 1
could not be replicated, an attempt was made to replicate the MLE
and lower bounds using the USEPA (2010) reported model pa-
rameters. Using a life table analysis that follows the methods pro-
vided in Appendix C of USEPA (2010) and the reported model
parameters, the MLE and lower bounds on dose for Hodgkin lym-
phoma and all leukemia could not be replicated. Using the available
parameters and results reported in USEPA (2010) and using the
USEPA's parameters, a 12e27% difference in unit risk values wasdetermined for leukemia, Hodgkin's lymphoma and NPC from
those reported by the USEPA (2010). However, when the life table
was adjusted to be consistent with the relative risk model that was
the basis of the b value used in USEPA (2010), the values reported by
the USEPA could be replicated.
In noting the potential differences in unit risk estimation, this
12e27% difference could be considered in combination with the
potential differences in unit risk from step 1 (differences in the
model results), as well as the potential impact of the differences in
risk from step 3. Therefore, the inability to replicate individual steps
in the process may result in unit risk estimates different from those
in USEPA (2010) by 100% or greater due to differences in the slope
factors (up to 100% difference) as well as differences in life table
analysis results (12e27%) that would be calculated following the
documentation provided in USEPA (2010).
Analyses were also conducted using the “peak” exposuremetric,
rather than the continuous metric relied upon by USEPA (2010) for
their evaluation. This was conducted using the same model (log-
linear Poisson stratiﬁed by calendar year, age sex, and race and
adjusted for pay category) as Beane Freeman et al. (2009), but in
contrast to the results reported by Beane Freeman et al. (2009), no
signiﬁcant relative risks were estimated (Table 4). Reasons for the
differences between the current analyses and those reported by
Beane Freeman et al. (2009) could include that the speciﬁc dates of
job start and job end were not provided, nor were the speciﬁc dates
that follow-up started or ended: only month and year were
reported.
3.1.6. Evaluation of model selection
In evaluating the potential ﬁt of the model to the data, there are
various tests that can be performed to look at the predictive power
of a model (e.g. R2 tests, c2 tests), to make comparison between
models (e.g. AIC and other log-likelihood tests) or graphical rep-
resentations of the data to visualize the ﬁt. However, since no such
statistics were provided in either Beane Freeman et al. (2009) or
USEPA (2010), comparisons can only be made among the models ﬁt
to the data in this current analysis. The R2 values reported for the
logistic regression performed in this analysis were uniformly poor
(i.e., 0.05 or less) indicating poor predictive ability of the models.
For the Poisson models, there were small values for the Pearson c2
value which, with the large sample size, achieved a better ﬁt to the
data (p-values close to 1). However, in graphs presented in this
analysis using the data at the end of follow-up, the rate of all leu-
kemias was plotted against the continuous exposure as well as the
model predicted rates estimated for both the Poisson regression
model (Fig. 1) and the logistic model (Fig. 2).2 These ﬁgures show
large variability in the observed rates in the low concentration re-
gion which subsequently makes comparison and evaluation of the
ﬁt of the model to the data difﬁcult. This variability also makes any
predictions made with models ﬁt to these data highly uncertain. In
addition, the predictions of extra risk provided by USEPA (2010)
Fig. 2. Comparison of estimated cases from the logistic regression model to number of cases of leukemia observed at the end of follow-up period in the Beane Freeman et al. (2009)
study. Observed and predicted results over full observed exposure range.
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observable range and involve upward extrapolation. The results are
estimates of extra risk approaching 1, which are unreasonable.
While each model provides predictions that “run through the
middle” of the data, it is clear that neither model can adequately
predict the exposure-response relationships or lack of pattern in
the lower concentration region (Figs. 1 and 2), as the data in this
region of the exposure-response curve appears to be comparable to
random variation. In the low concentration region, the data lack a
clear monotonic dose-response relationship, which may explain
lack of a signiﬁcant trend (p ¼ 0.08) even for the combination of all
leukemias. Overall, the models do not ﬁt the pattern of exposure-
response in the data. While the models appear to be more consis-
tentwith the data at concentrations greater than 10 ppm-years, this
comparison is largely inﬂuenced by two data points. It is possible
that this shape of the exposure-response curve may explain the
unusual nonlinearities in the estimates of extra risk provided by
USEPA (2010) (Tables 2 and 3). However, explaining this unusual
exposure-response behavior is difﬁcult due to the inability to
duplicate the unit risk estimates provided in USEPA (2010).4. Discussion
One of the greatest challenges in attempting to duplicate unit
risk factors estimated by USEPA is attempting to duplicate those
speciﬁcally based on epidemiological data. When USEPA has relied
upon animal data for the estimation of unit risk values, even when
the documentation provided is limited, there are guidelines avail-
able (USEPA, 2012) that provide speciﬁc steps and assumptions
used by USEPA in the dose-response analysis of animal data.
However, when epidemiological data are applied, there is not
comparable guidance, and the necessary additional detail may not
be provided in the IRIS documentation to allow for transparency
and the ability to duplicate risk values.
In the case of formaldehyde, the draft IRIS toxicological review
(USEPA, 2010) provided documentation largely on the estimation of
IURs from the cases of NPC from the NCI cohort reported by
Hauptmann et al. (2004), assuming that these methods could easily
be extended in an attempt to duplicate values for lymphohemato-
poietic cancers provided in an update to the NCI cohort by Beane
Freeman et al. (2009). The results from this assessment, inattempting to duplicate unit risk values for lymphohematopoietic
cancers, demonstrate that this is not the case.
Difﬁculty in duplication of results from each step of the process
of the estimates of IURs, following the steps as outlined by NRC
(2011), started with the initial step that involved duplication of
the b parameters from the log-linear Poisson regression model as
provided by Dr. Laura Beane Freeman to the USEPA. In the initial
step of the process, our results suggest no signiﬁcant association
between cumulative exposure to formaldehyde, which is the
exposure metric relied upon by USEPA (2010) for the estimation of
the IURs, and either all leukemias combined or acute myeloid
leukemia speciﬁcally. This lack of association is directly relevant to
evaluation of causality and should be considered earlier in the
determination of what endpoints likely are caused by exposure to
formaldehyde and therefore which associations might be relied
upon for the estimation of IURs. Based on the results for all leu-
kemias, as well as AML, with no signiﬁcant trends observed, it is not
appropriate to conduct dose-response modelling only on null
ﬁndings. In addition, while similar, the b values could not be
duplicated even with the availability of the raw data, which sug-
gests that the methods applied are not adequately documented in
USEPA (2010).
USEPA (2010) relied heavily upon the Beane Freeman et al.
(2009) study for risk estimation associated with lymphohemato-
poietic tumors, with the NRC (2011) committee noting that this
may be the only study with sufﬁcient exposure and dose-response
data needed for risk estimation. However, they also noted that this
study is notwithout weaknesses and these need to be considered. A
reanalysis of the raw data from the NCI study (Beane Freeman et al.,
2009) was conducted by Checkoway et al. (2015). While basic re-
sults were replicated, additional analyses of the associations of
speciﬁc lymphohematopoietic cancers, speciﬁcally acute myeloid
leukemia (AML) with various metrics of formaldehyde exposure
(peak, average, cumulative) and using a more standard deﬁnition of
peak exposure than that relied on by Beane Freeman et al. (2009)
were reported. The re-evaluation highlighted many of the limita-
tions in the data from this cohort, and the new analyses indicated
no clear association with AML. It is not clear why AML results had
not been reported in any of the updates of this study, and not
considered in the IRIS evaluation, given that AML has been high-
lighted as the lymphohematopoietic cancer most likely to be
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benzene.
The results from the current analysis for Hodgkin lymphoma
also provide estimates inconsistent with those reported by USEPA
(2010). Using the cumulative exposure metric, USEPA (2010) re-
ported no signiﬁcant trend for Hodgkin lymphoma. The current
analysis suggests a signiﬁcant trend (Table 1 e p ¼ 0.013), which is
consistent with the results from Checkoway et al. (2015) reporting
increased relative risk estimates for Hodgkin lymphoma in the
highest exposure categories of cumulative and peak exposures. As
noted in Checkoway et al. (2015), these ﬁndings are complicated
because there is little epidemiological support for chemical expo-
sures in the etiology of Hodgkin's lymphoma. There is an absence of
an increased risk for this cancer type in other occupational cohorts,
as well as the lack of a plausible biological mechanism. In addition,
NTP (2014) noted that because the evidence for Hodgkin lymphoma
is mainly limited to the NCI cohort study, a causal association is not
established. As with all leukemias, including AML, there are ques-
tions related to a causal association between cumulative formal-
dehyde exposure and this cancer type that suggest that the
estimation of a quantitative measure of risk using these data are
inappropriate.
NRC (2011) also highlighted that the modes of action for
formaldehyde-induced Hodgkin lymphoma and for leukemias have
not been established. Moreover, the studies that demonstrate the
lack of systemic delivery of formaldehyde following inhalation
exposure (Lu et al., 2011; Moeller et al., 2011; Edrissi et al., 2013; Yu
et al., 2015) draw into question the biological plausibility of form-
aldehyde causing any LHP cancer. NRC (2011) noted that
“Although EPA postulated that formaldehyde could reach the bone
marrow either as methanediol or as a byproduct of nonenzymatic
reactions with glutathione, numerous studies described above have
demonstrated that systemic delivery of formaldehyde is highly
unlikely at concentrations below those which overwhelm meta-
bolism according to sensitive and selective analytic methods that
can differentiate endogenous from exogenous exposures.”
Thus, substantial uncertainties remain in using both Hodgkin
lymphoma and leukemias (all or individual) for consensus cancer
risk estimation. Formaldehyde is rapidly metabolized and highly
reactive and, because it is an endogenous compound, a detectable
change in the natural background or endogenous levels would need
to occur in order to result in the potential for adverse effects.
Multiple studies using multiple species, including non-human
primates, have been conducted using a sensitive analytical
method that can measure endogenous versus exogenous formal-
dehyde DNA adducts (Yu et al., 2015; Edrissi et al., 2013; Moeller
et al., 2011; Lu et al., 2011). The results of these studies indicated
that inhaled formaldehyde was found to reach nasal respiratory
epithelium, but not other tissues distant to the site of initial contact.
These results suggest a lack of an ability for exogenous or inhaled
formaldehyde exposure to affect endogenously present concen-
trations of formaldehyde.
Although the Draft Review cites hypotheses proposed by Zhang
et al. (2010) regarding the theoretical development of leukemia
following inhalation of formaldehyde, there is no documented ev-
idence to support the validity of these hypotheses. In fact, Zhang
et al. (2010) note that their hypotheses related to mechanisms of
leukemia clearly require additional testing. The existing mecha-
nistic data for formaldehyde provide no evidence that exogenous
formaldehyde will be transported from the point of contact to
distant sites, but do provide evidence that formaldehyde does not
affect the relevant target cells for leukemia (bone marrow or pe-
ripheral blood) (Yu et al., 2015; Edrissi et al., 2013; Moeller et al.,2011; Lu et al., 2011).
Overall, the documentation of the methods applied by USEPA
lacks sufﬁcient transparency and detail for duplication of the unit
risk estimates provided in USEPA (2010), even with the availability
of the raw data from the Beane Freeman et al. (2009) study that
USEPA relied upon for estimation of the risk of Hodgkin lymphoma
or all leukemias. This lack of transparency and detail may result in
different estimates of unit risks, including invalid estimates, espe-
cially as initial analyses resulted in a lack of a signiﬁcant dose-
response relationship for selected endpoints.
In attempting to duplicate the USEPA (2010) calculations, difﬁ-
culties were encountered at each step, largely due to a lack of
critical information provided in the IRIS documentation. Even
though analyses were conducted multiple times with different
assumptions, all of which could be consistent with the description
provided by USEPA (2010), the unit risk values could not be
duplicated. The results of the analyses yielded conﬂicting and
different estimates with each step of the analysis, with differences
in each step up to a factor of 2. The inability to replicate individual
steps in the process may result in unit risk estimates different from
those in USEPA (2010) by 100% or greater due to differences in the
slope factors (up to 100% difference) as well as differences in life
table analysis results (12e27%). Perhaps most problematic, the ﬁrst
step of the analysis did not determine signiﬁcant exposure-
response relationships between formaldehyde and LHP endpoints
for themetric (cumulative exposure) needed in the estimation of an
IUR. The resulting analysis, while it can bemechanically performed,
provides no valid or useful insights on the risks of formaldehyde
exposure. Regulatory dependence on these analyses may therefore
lead to erroneous guidance, policies and laws.
These results highlight the necessity of clear and transparent
reporting of both methods and data used in the estimation of unit
risk values. Values provided by the IRIS program of USEPA are relied
upon by other federal and state agencies in regulatory decision-
making related to the development of standards and guidelines
for environmental, consumer product and workplace exposure to
chemicals. The inability to duplicate these types of values only es-
calates the scientiﬁc debate over the applicability of these stan-
dards and the scientiﬁc data necessary to support conclusions
regarding acceptable levels of human exposure to chemicals.
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